These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37028478)

  • 1. Spectral Analysis Based on Hemodynamic Habitat Imaging Predicts Isocitrate Dehydrogenase Status and Prognosis in High-Grade Glioma.
    Qiao J; Wu H; Liu J; Kang H; Wang S; Fang J; Zhang J; Zhang W
    World Neurosurg; 2023 Jul; 175():e520-e530. PubMed ID: 37028478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.
    Wu H; Tong H; Du X; Guo H; Ma Q; Zhang Y; Zhou X; Liu H; Wang S; Fang J; Zhang W
    Eur Radiol; 2020 Jun; 30(6):3254-3265. PubMed ID: 32078014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic habitat imaging with hemodynamic heterogeneity predicts individual progression-free survival in high-grade glioma.
    Qiao J; Kang H; Ran Q; Tong H; Ma Q; Wang S; Zhang W; Wu H
    Clin Radiol; 2024 Jun; 79(6):e842-e853. PubMed ID: 38582632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodel habitats constructed by perfusion and/or diffusion MRI predict isocitrate dehydrogenase mutation status and prognosis in high-grade gliomas.
    Liu J; Cong C; Zhang J; Qiao J; Guo H; Wu H; Sang Z; Kang H; Fang J; Zhang W
    Clin Radiol; 2024 Jan; 79(1):e127-e136. PubMed ID: 37923627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7 Tesla magnetic resonance spectroscopic imaging predicting IDH status and glioma grading.
    Cadrien C; Sharma S; Lazen P; Licandro R; Furtner J; Lipka A; Niess E; Hingerl L; Motyka S; Gruber S; Strasser B; Kiesel B; Mischkulnig M; Preusser M; Roetzer-Pejrimovsky T; Wöhrer A; Weber M; Dorfer C; Trattnig S; Rössler K; Bogner W; Widhalm G; Hangel G
    Cancer Imaging; 2024 May; 24(1):67. PubMed ID: 38802883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association between Whole-Brain MR Spectroscopy and IDH Mutation Status in Gliomas.
    Goryawala M; Saraf-Lavi E; Nagornaya N; Heros D; Komotar R; Maudsley AA
    J Neuroimaging; 2020 Jan; 30(1):58-64. PubMed ID: 31868291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
    Nguyen TB; Melkus G; Taccone M; Moldovan ID; Ghinda D; Gotfrit R; Torres CH; Zakhari N; Chakraborty S; Woulfe J; Jansen G; McInnes MD; Thornhill RE; Cameron I; AlKherayf F
    J Magn Reson Imaging; 2021 Feb; 53(2):416-426. PubMed ID: 32940938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma.
    Joo B; Han K; Ahn SS; Choi YS; Chang JH; Kang SG; Kim SH; Zhou J; Lee SK
    Eur Radiol; 2019 Dec; 29(12):6643-6652. PubMed ID: 31175415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
    Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
    Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
    Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
    J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
    Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
    Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasively evaluating the grade and IDH mutation status of gliomas by using mono-exponential, bi-exponential diffusion-weighted imaging and three-dimensional pseudo-continuous arterial spin labeling.
    Guo D; Jiang B
    Eur J Radiol; 2023 Mar; 160():110721. PubMed ID: 36738600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
    Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
    Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
    Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
    AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo Metabolic Profiles as Determined by
    Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
    Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
    Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
    J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
    Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
    Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
    Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
    J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
    Zhang B; Chang K; Ramkissoon S; Tanguturi S; Bi WL; Reardon DA; Ligon KL; Alexander BM; Wen PY; Huang RY
    Neuro Oncol; 2017 Jan; 19(1):109-117. PubMed ID: 27353503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.